<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gallium Ga-68 DOTATATE: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gallium Ga-68 DOTATATE: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gallium Ga-68 DOTATATE: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="112901" href="/d/html/112901.html" rel="external">see "Gallium Ga-68 DOTATATE: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46858912"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Netspot</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46687464"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F46859480"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b>
<b>IV:</b> 2 MBq/kg (0.054 mCi/kg); maximum dose 200 MBq (5.4 mCi). Begin PET scanning 40 to 90 minutes after completion of gallium Ga 68 dotatate administration.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990523"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987830"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dop drugH1Div" id="F46859481"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="112901" href="/d/html/112901.html" rel="external">see "Gallium Ga-68 DOTATATE: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging:</b> Infants, Children, and Adolescents: IV: 2 MBq/kg (0.054 mCi/kg); maximum dose: 200 MBq/dose (5.4 mCi/dose). Begin positron emission tomography (PET) scanning 40 to 90 minutes after completion of gallium Ga 68 dotatate administration.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112274"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112275"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F46732774"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site, pain at injection site</p></div>
<div class="block coi drugH1Div" id="F46687487"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling. </p></div>
<div class="block war drugH1Div" id="F46859470"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: May be an irritant; extravasation may result in local irritation. Avoid extravasation. If extravasation occurs, stop infusion and restart in a different injection site. Irrigate extravasation site with sodium chloride solution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including rash and pruritus and rarely anaphylaxis-related reaction and angioedema, have occurred; cases usually resolved without intervention or with symptomatic management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation accumulation: Gallium Ga 68 dotatate administration contributes to the patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Patients should avoid close contact with infants and pregnant patients during the first 12 hours following administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risk for misinterpretation: Uptake of gallium Ga 68 dotatate reflects the level of somatostatin receptor density in neuroendocrine tumors (NETs). Uptake may also be seen in other tumor types (eg, tumors derived from neural crest tissue), sites of splenosis, or other pathologic conditions (eg, thyroid disease, subacute inflammation), or normal physiologic variants (eg, uncinated pancreatic process). Interpret PET images visually, and the uptake may require confirmation by histopathology or other assessments. A negative scan in patients without a history of NETs, as well as patients suspected of ectopic ACTH-secreting tumors, does not rule out presence of NETs.</p></div>
<div class="block foc drugH1Div" id="F46858913"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Netspot: Lyophilized dotatate mixture and reaction buffer solution [to be combined with Ga 68 (not included)]</p></div>
<div class="block geq drugH1Div" id="F46858911"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53685422"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dotatoc Ga 68 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5-4mCi/ML (per each): $3,637.92</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F46859485"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an IV bolus. Immediately prior to administration, measure and verify the radioactivity in the syringe with a dose calibrator to ensure radioactivity administered is within ±10% of the recommended dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Imaging should include whole body acquisition from skull to mid-thigh. Begin PET scanning 40 to 90 minutes after administration of gallium Ga 68 dotatate.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should drink a sufficient amount of water to ensure adequate hydration prior to administration and in the first hours following administration and void frequently following administration to reduce radiation exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients receiving a somatostatin analog, the manufacturer's labeling recommends to image patients with gallium Ga 68 dotatate just prior to administration of a long-acting somatostatin analog. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatate.</p>
<p style="text-indent:-2em;margin-left:2em;">May be an irritant; extravasation may result in local irritation. Avoid extravasation. If extravasation occurs, stop infusion and restart in a different injection site. Irrigate extravasation site with sodium chloride solution.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. When handling and administering, follow appropriate safety measures to minimize radiation exposure during administration; use waterproof gloves and effective shielding, including syringe shields.</p></div>
<div class="block admp drugH1Div" id="F52614649"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Administer as an IV bolus. Immediately prior to administration, measure and verify the radioactivity in the syringe with a dose calibrator to ensure radioactivity administered is within 10% of the recommended dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Imaging should include whole body acquisition from skull to mid-thigh. Begin PET scanning 40 to 90 minutes after administration of gallium Ga 68 dotatate.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should drink a sufficient amount of water to ensure adequate hydration prior to administration and in the first hours following administration and void frequently following administration to reduce radiation exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients receiving a somatostatin analog, the manufacturer's labeling recommends to image patients with gallium Ga 68 dotatate within 24 hours of administration of a short-acting somatostatin analog or just prior to administration of a long-acting somatostatin analog.</p>
<p style="text-indent:-2em;margin-left:2em;">May be an irritant; extravasation may result in local irritation. Avoid extravasation. If extravasation occurs, stop infusion and restart in a different injection site. Irrigate extravasation site with sodium chloride solution.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. When handling and administering, follow appropriate safety measures to minimize radiation exposure during administration; use waterproof gloves and effective shielding, including syringe shields.</p></div>
<div class="block use drugH1Div" id="F46687466"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b> Use with positron emission tomography (PET) (after radiolabeling with Ga 68)  for localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients.</p></div>
<div class="block mst drugH1Div" id="F46687462"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gallium Ga 68 dotatate may be confused with copper Cu 64 dotatate, gallium citrate Ga-67, gallium Ga 68 PSMA-11.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46769551"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46769548"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the diagnostic effect of Gallium Ga 68 Dotatate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: May diminish the diagnostic effect of Gallium Ga 68 Dotatate. Specifically, a false negative PET scan may occur if Gallium GA 68 Dotatate is used during treatment with somatostatin analogs. Management: It is recommended to image with gallium Ga 68 dotatate positron emission tomography (PET) just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatate.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F46859448"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F46859449"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if gallium ga 68 dotatate is present in breast milk. The manufacturer recommends breastfeeding be interrupted and breast milk discarded for 12 hours after administration.</p></div>
<div class="block pha drugH1Div" id="F46859474"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gallium Ga 68 dotatate is a radioactive diagnostic agent. Ga 68 dotatate binds to cells that express somatostatin receptors including malignant cells, which overexpress somatostatin type 2 (sstr2) receptors. Gallium 68 (<sup>68</sup>Ga) is a beta+ emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging. Tumors which do not express somatostatin receptors will not be visualized by imaging.</p></div>
<div class="block phk drugH1Div" id="F46859476"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Extensive to all somatostatin type 2 (sstr2)-expressing organs (including pituitary, thyroid, spleen, adrenals, kidney, pancreas, liver, and salivary glands).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Gallium Ga 68 dotatate decays with a half-life of 68 minutes to stable zinc ZN 68.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (12% in first 4 hours).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Netspot (Gallium Ga 68 dotatate) [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA Inc; December 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 108440 Version 57.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
